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ABSTRACT
OBJECTIVE: The Humulus lupulus L. plant (hops) is used as a herbal medicinal product for 
anxiety/mood disorders. Our aim was to study the effects of a hops dry extract on self-reported 
depression, anxiety and stress levels in young adults. DESIGN: Apparently healthy young 
adults from our university completed the Depression Anxiety Stress Scale-21 (DASS-21) and 
those reporting at least mild depression, anxiety and stress were invited to complete the study 
intervention. This followed a randomized (1:1), placebo-controlled, double-blind, crossover 
design with two 4-week intervention periods (hops or placebo; two 0.2 gr capsules once daily) 
separated by a 2-week wash-out. Anthropometric measurements, DASS-21 assessments and 
measurements of morning cortisol plasma levels were performed at the beginning and the 
end of the 4-week treatment periods. RESULTS: 36 participants (Females/Males: 31/5; age: 
24.7±0.5 years) completed the study intervention (attrition: 6/42). No significant changes in body 
weight and composition or morning circulating cortisol were noted with the hops or placebo. 
Significantly decreased DASS-21 anxiety, depression and stress scores were documented with 
hops (9.2±7.3 vs. 5.1±5.9, 11.9±7.9 vs. 9.2±7.4, and 19.1±8.1 vs. 11.6±8.1; all p values <0.05), 
which were significantly greater compared to those caused by the placebo (all p values <0.05). 
CONCLUSION: In otherwise healthy young adults reporting at least mild depression, anxiety
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INTRODUCTION
Chronic stress is frequently manifested with anxiety 
and/or depressive symptomatology, which progres-
sively may lead to a spectrum of behavioral and/or 
somatic disorders.1-4 Currently, anxiety and mood 
disorders constitute the most prevalent mental health 
problems in the general population, which often coexist 
particularly in primary care settings and the commu-
nity.5-7 Indeed, the lifetime prevalence of any mood 
disorder is estimated to average 12%, whilst large 
population-based studies show that up to 33.7% of 
individuals in the general population are affected by 
an anxiety disorder in their lifetime.5,6 Moreover, as 
these stress-related disorders frequently affect young 
individuals during their most active years, there is 
also a significant impact on their quality of life and 
productivity, with the World Health Organization 
(WHO) recognizing depression as the leading cause 
of disability worldwide.8
In addition, anxiety disorders and depression have 
been traditionally amongst the most prominent reasons 
for using complementary therapies.9-11 Of note, such 
therapies are more common in patients reporting 
mental health-related problems than in the rest of the 
population, and they are also used more frequently 
compared to conventional therapies by individu-
als with self-defined anxiety disorders and severe 
depression.9 Thus, it is not surprising that most of 
the patients visiting mental health care providers for 
anxiety and/or mood disorders report the use of com-
plementary therapies, with herbal medicinal products 
being used more frequently.10-12 Interestingly, the use 
of these therapies is increasing, not only because of 
dissatisfaction with conventional medicine, but also 
due to a holistic orientation to health, particularly 
regarding options to reduce stress/anxiety, and to a 
broader attitude towards seeking non-prescription and 
non-pharmacological treatments with fewer adverse 
effects.11-13
Amongst the plants used for medicinal purposes, 
the plant named Humulus lupulus L (Family: Can-
nabaceae) has a long-standing tradition of medici-
nal use in Europe.14 Hops is the common name of 
the strobiles (cones) of the female inflorescences 
of the Humulus lupulus L. plant and is widely used 
as a bittering agent in the beer brewing industry, as 
well as a herbal medicinal product mostly for sleep 
disturbances.15 Thus, hops in the form of herbal tea, 
infusions, liquid/alcoholic extracts, tinctures and 
powdered herbal substances have traditionally been 
used for the relief of insomnia, excitability and restless-
ness associated with tension headaches and nervous 
tension.14,15 Indeed, the German Commission E has 
approved the use of hops for sleep disturbances and 
mood disorders, such as anxiety and restlessness.16 
Data from in vivo studies in rats have shown that a 
hops extract and its fraction containing alpha-bitter 
acids (humulones) exert significant sedative and 
antidepressant effects, whilst hops beta-acids (lupu-
lones) appear to also exhibit antidepressant activity 
with fewer sedative effects, probably by affecting 
gamma-aminobutyric acid (GABA) neurotransmission 
activity.17,18 Moreover, in vitro binding experiments 
on selected central nervous system (CNS) receptors 
using a fixed combination valerian-hops extract and its 
individual components have shown that hops interact 
with certain serotonin (5-HT6) and melatonin (ML1) 
receptor subtypes, which are involved in various 
CNS functions related to stress activity, relaxation, 
circadian rhythms and sleep.19 
Despite the popularity of hops, particularly in 
central Europe, as a sedative and mood-enhancing 
herbal medicinal product, there is a marked paucity 
of high-quality, placebo-controlled clinical studies on 
the efficacy of hops in reducing stress-related symp-
tomatology. Therefore, the aim of the present study 
was to explore the effects of a commercially available 
hops dry extract on self-reported depression, anxiety 
and stress levels in apparently healthy young adults.
and stress symptoms, daily supplementation with a hops dry extract can significantly improve 
all these symptoms over a 4-week period. These beneficial effects agree with the indication of 
hops for anxiety/mood disorders and restlessness, as approved by the German Commission E.
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MATERIAL AND METHODS
Study protocol - Design
The study was approved by the Institutional Review 
Board of Harokopio University, Athens, Greece, and 
was conducted in accordance with the principles and 
recommendations of the Declaration of Helsinki.20 The 
study protocol had a randomized, placebo-controlled, 
double-blind, crossover design with two 4-week in-
tervention periods separated by a 2-week wash-out 
period. Study participants were allocated to start the 
intervention with either placebo or hops dry extract 
capsules (two 0.2 g capsules once daily in the evening, 
which is the recommended daily dose for this hops 
supplement) according to a pre-established computer 
generated randomization schedule (randomization ratio: 
1:1). Placebo and hops (0.2 g hops extract; Melcalin® 
HOPs, Biotekna Srl., Venice, Italy) capsules for the 
study treatment were kindly provided by Biotekna 
Srl. (Biotekna Srl., Venice, Italy). In the context of 
this study, placebo and hops capsules were provided 
in sealed, identical containers/bottles, each covering a 
4-week treatment period. Each of these containers was 
coded as either “I” or “II” in order to blind both study 
investigators and participants to the randomization/
treatment until the study was completed. Each study 
participant was provided with one capsule container 
at the beginning of each intervention period, whilst all 
capsule containers were collected at the end of each 
4-week period in order to count any unused capsules 
as a measure of compliance with the study treatment. 
For a 2-week period prior to the study initiation and 
throughout the total duration of the study, all par-
ticipants were asked to abstain from hops-containing 
products (e.g. beer) and other supplements/vitamins 
(e.g. valerian or St. John’s wort). In addition, all study 
subjects were asked to refrain from significant changes 
to their dietary habits and maintain their usual activity 
levels throughout the study duration. Moreover, all 
participants were also instructed to keep a record of 
any symptoms/signs of adverse events and/or illnesses, 
as well as any use of medications for the duration of 
the study, and these records were checked by the study 
investigators at the end of both experimental periods.
Study participants
The cohort of this study was recruited from young 
Caucasian adults (age >18 years) attending Haroko-
pio University, Athens, Greece at an under- or post-
graduate level. The study exclusion criteria included 
any systemic disease (e.g. neurological or psychiatric 
disorders, including clinically diagnosed anxiety 
disorders and depression) or treatment (e.g. sedative 
or antidepressant medications and relevant supple-
ments/preparations) which could interfere with the 
study objectives so that only apparently healthy adults 
were recruited into the study. Furthermore, individuals 
with recent (within the past two months) significant 
changes in body weight (>3% of total body weight) 
and/or physical activity levels as well as subjects 
with known drug and/or alcohol use disorders were 
excluded from recruitment. All study participants 
completed a psychological profile assessment via 
the validated, self-reported study questionnaire (i.e., 
the Depression Anxiety Stress Scale-21, as detailed 
in the following section) and volunteers with scores 
indicating at least mild depression, anxiety and stress 
levels were further invited to participate in the inter-
vention part of the study. All study procedures were 
completed during an exam-free period to avoid bias 
relating to exam-related stress. Each participant was 
fully informed about the study aims, design and ex-
perimental procedures and provided written informed 
consent before participating in the study. 
Study protocol assessments
Anthropometry
Anthropometric measurements were performed 
for all study subjects at the beginning and the end 
of the two 4-week treatment periods. Body weight 
and height were measured at our university research 
unit in participants without shoes or heavy clothing. 
Body weight (BW) was measured to the nearest 0.5 
kg and height to the nearest 1 cm. Body mass index 
(BMI) was calculated as body weight in kilograms 
divided by the square of the height in meters. Body 
composition analyses, including body fat mass (FM: 
%BW), total body water (TBW: %BW) and extracel-
lular water (ECW: %BW), were also performed at 
the same time-points using a calibrated, standardized, 
dual frequency bioelectrical impedance analysis (BIA) 
instrument (BIA-ACC device, Biotekna Srl., Venice, 
Italy), as previously described.21
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Assessments of self-reported depression,  
anxiety and stress symptomatology
Depression, anxiety and stress symptomatology was 
assessed in all study participants using the validated 
Greek translation of the Depression Anxiety Stress 
Scale-21 (DASS-21), which has been shown to be 
reliable in the Greek adult general population with 
psychometric properties similar to those reported in 
the international literature.22 The DASS-21 is a well-
established, validated, self-rating scale which measures 
the magnitude of three negative emotional states, 
i.e. depression, anxiety and stress. This instrument 
is considered both sensitive and accurate and thus 
is widely applied in research. Briefly, the DASS-21 
consists of 21 self-reporting items with seven items 
in each of the three subscales (depression, anxiety, 
and stress, respectively), documenting the relevant 
symptomatology over the past week.23 Each item 
comprises a statement and four ordinal responses, 
which are rated as: (i) “Did not apply to me at all 
- NEVER”; (ii) “Applied to me to some degree, or 
some of the time - SOMETIMES”; (iii) “Applied to 
me to a considerable degree, or a good part of the 
time - OFTEN”; and (iv) “Applied to me very much, 
or most of the time - ALMOST ALWAYS”, and are 
assigned a score of 0, 1, 2 and 3, respectively. Scores 
from the seven items in each subscale are summed up 
to yield a single subscale score. Each of these subscale 
scores is further multiplied by two (subscale score 
range: 0-42) in order to compare it with the normative 
data of the long form of the DASS instrument which 
has 42 items (DASS-42). Notably, the DASS-21 has 
the same factor structure and yields similar results 
to the DASS-42, while it requires half the time to be 
administered (5-10 mins). Subscale scores equal or 
higher than 10, 8 and 15 indicate the presence of at 
least mild depression, anxiety and stress symptoma-
tology, respectively. Higher scores in each subscale 
indicate even greater severity of the corresponding 
depression, anxiety and stress symptoms.23
Cortisol plasma levels measurements
Blood sampling for measurements of morning 
cortisol plasma levels was performed in all study 
participants at the beginning and the end of the two 
4-week intervention periods, as per study protocol. 
All venous blood samples were collected between 
0800 and 0900 hours, after overnight fasting (10 hours 
of overnight fasting without food or drink intake, 
except for water). All plasma cortisol measurements 
were carried out on an ΑΙΑ-600ΙΙ analyzer (TOSOH 
Bioscience, Inc., South San Francisco, CA, USA) 
using a competitive fluorescence enzyme immunoas-
say based on individual test cups, according to the 
manufacturer’s instructions (ST AIA-PACK CORT, 
TOSOH Bioscience, Inc., South San Francisco, CA, 
USA; assay range: 0.2-60 µg/dL; intra- and inter-assay 
coefficient of variation <5.0%).
Statistical analysis
Normally distributed variables are presented as 
means ± standard error (SEM), unless otherwise 
stated. Categorical variables are presented as frequen-
cies. Differences between and within groups were 
evaluated using two-way (group X time) analysis of 
variance (ANOVA) and Repeated-Measures ANOVA, 
as appropriate. The Shapiro-Wilk test was used to 
evaluate the normality of the distribution of quan-
titative variables. Correlations between continuous 
variables with skewed distributions were tested by 
the Spearman’s rank correlation coefficient. Associa-
tions between continuous and categorical variables 
were evaluated using the Pearson chi-square test and 
the Mann-Whitney test, where appropriate. Statisti-
cal significance was considered with a two-sided p 
value of <0.05. The Statistical Package for the Social 
Sciences, SPSS, version 18.0 (SPSS Inc., Chicago, 
IL, USA) was used to analyze data.
RESULTS
Of the 126 adults who completed the DASS-21 
questionnaire, 42 individuals (Females/Males: 38/4; 
age: 25±3.9 years) were eligible based on the study 
inclusion/exclusion criteria and consented to participate 
in the intervention part of the study. Figure 1 pres-
ents the CONSORT flow diagram of all participants 
throughout the study stages. Six of the study subjects 
who entered the intervention part of the study failed 
to complete the first intervention arm as per protocol 
and were excluded from further analyses (Figure 1; 
study attrition rate: 14.2%). None of the study par-
ticipants experienced adverse/side effects from the 
study treatment (hops extract or placebo).
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The key baseline characteristics of the study par-
ticipants (N= 36) who completed the two 4-week 
intervention periods (placebo and hops) of this double-
blind, randomized, crossover study are presented in 
Table 1. The study participants exhibited no significant 
changes in body weight, BMI and body composition 
parameters (FM; TBW; ECW) with the two study 
treatments (data not shown; all corresponding p values 
Figure 1. Flow diagram of all participants throughout the study stages.
>0.05). Similarly, neither the hops nor the placebo 
induced significant changes in the morning cortisol 
plasma levels in the study cohort (17.7±5.8 μg/dL vs. 
17.6±6.3 μg/dL and 18.5±5.9 μg/dL vs. 18.9±4.8 μg/
dL, respectively; both p values >0.05).
A significant decrease in the DASS-21 anxi-
ety score was noted with both the hops (9.2±7.3 
vs. 5.1±5.9; p=0.003) and the placebo (8.3±7.1 vs. 
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6.2±5.6; p=0.041), which was significantly greater 
with the hops compared to the placebo (p=0.009) 
(Figure 2). In addition, the DASS-21 depression 
score decreased significantly after the hops (11.9±7.9 
vs. 9.2±7.4; p <0.001) and the placebo (11.8±9.2 vs. 
10.7±8.6; p=0.005), with a significantly more potent 
effect following the hops treatment compared to pla-
cebo (p=0.001) (Figure 3). Moreover, the DASS-21 
stress scores were also significantly reduced with 
the hops and the placebo study treatments (19.1±8.1 
vs. 11.6±8.1; p=0.003, and 17.8±9.9 vs. 15.1±8.8; 
p=0.022, respectively), with hops again inducing a 
significantly greater effect than the placebo (p=0.009) 
(Figure 4).
Finally, no correlations were identified between 
any of the three DASS-21 subscale scores and base-
line or post-treatment study variables, including body 
weight, BMI, body composition parameters (FM; 
TBW; ECW) and morning cortisol plasma levels 
(data not shown).
DISCUSSION
The primary objective of this study was to explore 
potential effects of a commercially available hops dry 
extract on self-reported depression, anxiety and stress 
symptomatology in apparently healthy young adults. 
Table 1. Selected baseline characteristics of the study participants 
(N= 36) who completed both the two 4-week intervention periods 
(placebo and hops) of this double-blind, randomized, crossover study 
Baseline variable Study cohort (N= 36)
Gender (Females/Males) 31/5
Age (years) 24.7 ± 0.5
Body Weight (kg) 62.1 ± 1.3
BMI (kg/m2) 22.7 ± 0.4
Fat Mass (% BW) 23.8 ± 0.8
Total Body Water (% BW) 49.9 ± 0.5
Extra Cellular Water (% BW) 47.1 ± 0.4
DASS-21 Depression Score 11.9 ± 1.0
DASS-21 Anxiety Score 8.8 ± 0.8
DASS-21 Stress Score 18.4 ± 1.1
Morning Plasma Cortisol (μg/dL) 18.1 ± 0.7
BMI: body mass index; BW: body weight; DASS-21: Depression 
anxiety stress scale-21; Data presented as means ± standard error. Figure 2. Depression anxiety stress scale-21 (DASS-21) anxiety 
scores at baseline and after hops and placebo 4-week treatment. 
Data are presented as means ± standard error. *: p=0.041 be-
fore vs. after placebo treatment; #: p=0.003 before vs. after hops 
treatment; §: p=0.009 hops treatment vs. placebo treatment.
Figure 3. Depression anxiety stress scale-21 (DASS-21) de-
pression scores at baseline and after hops and placebo 4-week 
treatment. Data are presented as means ± standard error. 
*: p=0.005 before vs. after placebo treatment; #: p <0.001 before 
vs. after hops treatment; §: p=0.001 hops treatment vs. placebo 
treatment.
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als suffering from depression because of the known 
sedative effects of hops, which may accentuate de-
pressive symptoms and potentiate the sedative effects 
of existing therapy.14,24 In regard to this point, our 
study findings suggest that hops may have an overall 
beneficial mood-enhancing effect without significant 
adverse/side effects in treatment-naïve individuals 
presenting with symptoms of both depression and 
anxiety/stress. Of note, this presence of depressive/
anxiety comorbidity is a frequent problem in everyday 
clinical practice, since anxiety and mood disorders 
often coexist, particularly in individuals in the general 
population.7 Additional clinical studies are required 
to further explore potential effects (beneficial and 
adverse/side effects) of hops in patients with depres-
sion not associated with increased anxiety/stress and 
in cases of anergic or atypical depression.
The pathophysiologic relationship between chronic 
stress and clinical manifestations of depression and/
or anxiety is complex, with melancholic depression 
representing a typical example of dysregulated stress 
response and hyperactivation of the stress system.1-4 
Indeed, the stress system consists of a highly in-
terconnected neuroendocrine infrastructure, which 
is located both in the CNS and the periphery. The 
central control stations of this system are positioned 
in the hypothalamus and the brain stem, including 
primarily the parvocellular corticotropin-releasing 
hormone (CRH) and arginine-vasopressin (AVP) 
neurons of the paraventricular hypothalamic nuclei, 
as well as the locus coeruleus/norepinephrine system.1 
Furthermore, the hypothalamic-pituitary-adrenal (HPA) 
axis and the efferent sympathetic/adrenomedullary 
system constitute the main effector limbs via which 
the CNS regulates the adaptive stress responses.1 
Based on the documented effects induced by the hops 
treatment in our study, it is plausible that hops may 
affect one or more of these stress system centers/com-
ponents, thereby reducing the chronic stress-related 
over-activity and resulting in improvement of the 
manifested depression/anxiety symptoms. However, 
our study results showed no significant changes in 
the morning plasma levels of cortisol, which is the 
final hormonal effector of the HPA axis.1-4 This may 
suggest either that hops has no significant impact on 
basal circulating cortisol levels or that it may have 
more subtle effects on the circadian rhythm of the 
Applying a randomized, placebo-controlled, double-
blind, crossover study design, our findings in a cohort 
of otherwise healthy young adults with at least mild 
self-reported depression, anxiety and stress symptoms 
revealed a significant reduction in the levels of all 
these symptoms with hops which was significantly 
greater compared to placebo (Figures 2 to 4). These 
results are in accord with the traditional use and the 
indication of hops for mood disorders, anxiety and 
restlessness, as approved by the German Commis-
sion E.14,16 To date, most of the clinical data on the 
effects of hops in humans are from studies utilizing 
hops as part of a combination preparation, typically 
with valerian,14 and hence it is not feasible to draw 
safe conclusions regarding direct mood-enhancing 
effects of hops based on these studies. To the best of 
our knowledge, this is the first placebo-controlled 
clinical study showing that a hops extract alone can 
significantly improve symptoms relating to both de-
pression and increased anxiety/stress, thus revealing 
these hops-specific beneficial effects.
Interestingly, it has been suggested in the literature 
that hops should be taken with caution by individu-
Figure 4. Depression anxiety stress scale-21 (DASS-21) stress 
scores at baseline and after hops and placebo 4-week treatment. 
Data are presented as means ± standard error. *: p=0.022 be-
fore vs. after placebo treatment; #: p=0.003 before vs. after hops 
treatment; §: p=0.009 hops treatment vs. placebo treatment.
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HPA axis and the diurnal variation of circulating 
cortisol. To identify such potential effects, further 
studies with a more complex study design would be 
required, utilizing multiple serial sampling of blood 
or saliva in order to explore hypothesized changes 
in the diurnal variation of cortisol levels. 
Further underlying mechanisms may also be impli-
cated in the effects of hops in the central stress system. 
Indeed, in vitro data indicate that hops may affect the 
GABA synthesis/metabolism and the GABAergic 
neurotransmission activity in the CNS.15,18,25-28 Impor-
tantly, GABA is the key inhibitory neurotransmitter 
implicated in the regulation of neuronal excitability 
and central stress system activity, acting mostly as a 
brake on the stimulated neural circuitry during stress.1 
Not surprisingly, low GABA levels in the CNS are as-
sociated with anxiety, restlessness and depression.29-32 
Thus, hops could potentially exert anxiolytic and/or 
antidepressant effects by modulating the levels and/
or activity of GABA in the CNS.15,18,25-28 However, 
the evidence supporting this hypothesis is based on 
preliminary data from in vitro experimental studies, 
which need to be corroborated by in vivo and clinical 
data. Similarly, based on in vitro binding experiments 
hops appears to interact with both serotonin (5-HT6) 
and melatonin (ML1) receptor subtypes in the CNS,19 
hence its anxiolytic and/or antidepressant effects may 
also involve the corresponding neural circuits, which 
have a well-established role in depression and the 
regulation of the central stress system and circadian 
rhythms.1,28 
Finally, another mechanism that may contribute 
to the hops-induced effects noted in our study is 
improvement in the sleep pattern/quality due to the 
sedative activity of hops.14,15 This has also been sug-
gested in two studies by Franco et al. which used 
non-alcoholic beer as a dietary source of hops over 
a 2-week period in 30 university students and 17 
healthy female nurses, respectively.33,34 Both these 
studies reported improvement in night sleep quality 
(e.g. reduced sleep latency), with the latter study 
suggesting that the effects on sleep quality were also 
reflected in decreased self-reported anxiety levels, 
as measured by the State-Trait Anxiety Inventory.34 
However, these two studies were not conducted in 
a blinded manner, lacked a placebo-controlled arm 
and had a non-standardized source of hops, thus 
limiting the interpretation and implications of the 
reported findings, particularly regarding the hops 
effects on anxiety levels through improved sleep 
quality. In order to explore this hypothesis, well-
designed, placebo-controlled studies with subjective 
and objective measures of sleep quality, quantity and 
architecture will be required.
LIMITATIONS 
A limitation of this study is that the depression, 
anxiety and stress symptomatology of the participants 
was self-reported. However, the DASS-21 is a well-
validated instrument, which is shown to accurately 
capture the underlying symptoms of these emotional 
states and is widely applied in this type of research.23 
Furthermore, complimentary/herbal medicines are 
used more frequently by individuals with self-defined 
anxiety and mood disorders,9 thus our study cohort 
represents a highly relevant population of particular 
research interest appropriate for exploring the effects 
of a commercially available, non-prescription hops 
dry extract supplement on depression and anxiety/
stress symptoms.
In this study, a random sample from the under- and 
post-graduate students at our university was recruited. 
A recruitment/selection bias may thus have existed 
in the recruitment process of our study cohort, as the 
study was advertised only to our student body. Such 
limitations are relatively common in this type of 
research, yet it was also our intention to explore this 
specific intervention in young adults with undiagnosed 
depression and anxiety/stress symptomatology, as the 
consequences of untreated anxiety and mood disorders 
in this age group are profound on both quality of life 
and productivity. Of note, our study was conducted in 
an exam-free period of the academic year, so that our 
study cohort can be considered at least to an adequate 
degree representative of the Greek general population 
of otherwise healthy young adults.
It should also be noted that in our study we 
documented a significant effect of the placebo in 
decreasing the self-reported depression, anxiety 
and stress levels. These placebo effects may be 
documented in the context of such interventions 
to treat depression and/or anxiety/stress disorders, 
especially since anxiety reduction and release of 
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endogenous opioids (e.g. dopamine and endorphins) 
are considered among the putative mechanisms me-
diating the placebo effect(s).35-38 However, despite 
the noted placebo effects, our study findings have 
allowed us to identify the significantly greater ef-
fects of the hops dry extract used as compared to 
placebo. This further highlights the importance of 
blinded, placebo-controlled study designs, particu-
larly in studies focused on anxiety/depression and/
or complementary medicine. Notably, it has been 
suggested that a “balanced crossover design” may 
be applied in order to further address issues relating 
to interactions between drug-specific and unspecific 
effects; however, this design has practical disadvan-
tages (i.e. it requires four study groups and thus an 
increased number of participants) and raises certain 
ethical issues (e.g. in this study design, in addition 
to the two typical crossover study groups, one study 
group receives the drug twice and another group 
receives the placebo twice instead of switching from 
the study drug to placebo or vice versa).39,40
Finally, our study assessments included profiling 
only of morning cortisol plasma levels which did not 
detect significant changes with the study intervention. 
In order to further explore potential effects of hops 
supplementation on the diurnal variation of stress 
system activity, additional studies would be required 
with serial sampling of blood and/or saliva to assess 
any changes in relevant biomarkers, such as salivary 
alpha-amylase (a non-invasive biomarker for the 
sympathetic nervous system activity).41 
CONCLUSION
Our study presents novel data showing that daily 
supplementation with a commercially available hops 
dry extract for a 4-week period in a cohort of otherwise 
healthy young adults with at least mild self-reported 
depression, anxiety and stress symptoms can signifi-
cantly reduce the levels of all these symptoms. This 
finding adds to the existing literature on the hops-
induced effects, since most of the existing clinical 
studies have used combinations of hops with other 
sedative plant extracts. Longer studies are required 
to explore the long-term efficacy and safety of this 
intervention, which should be also studied in older 
patients with depression and/or anxiety/stress disorders. 
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